Scarica l'app Stockscreener
755.00
0.58%
-3.91
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$758.91
Aprire:
$760.58
Volume 24 ore:
175.25K
Relative Volume:
0.18
Capitalizzazione di mercato:
$79.30B
Reddito:
$14.25B
Utile/perdita netta:
$4.58B
Rapporto P/E:
18.08
EPS:
41.7701
Flusso di cassa netto:
$3.88B
1 W Prestazione:
-7.11%
1M Prestazione:
+1.79%
6M Prestazione:
+32.24%
1 anno Prestazione:
+9.21%
Intervallo 1D:
$754.27
$766.64
Intervallo di 1 settimana:
$743.94
$821.11
Portata 52W:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Confronta REGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
754.51 | 79.76B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.19 | 115.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ARGX
Argen X Se Adr
|
806.53 | 50.16B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
361.61 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
348.42 | 38.85B | 4.98B | 69.59M | 525.67M | 0.5197 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2025-12-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Iniziato | HSBC Securities | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Regeneron (REGN) and Progyny (PGNY) - The Globe and Mail
Allergic Rhinitis Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Regeneron Pharma, Allergy Therapeutics, Inmunotek, UCB Pharma, Orexo AB, Hyloris Pharma - Barchart.com
Regeneron's Yancopoulos on Hearing Loss Gene Therapy, Weight Loss Drugs - marketscreener.com
JP Morgan 2026: Regeneron Focusing on Broad Pipeline Development - Pharmaceutical Executive
JPM26 Day 1: Obesity Front-and-Center, Q4 Sales Beats - BioSpace
Regeneron Pharmaceuticals (BIT:1REGN) Price Target Increased by 11.61% to 743.10 - Nasdaq
PKO Investment Management Joint Stock Co Trims Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharma price target raised to $820 from $800 at Raymond James - Investing.com UK
Market Review: What is the fair value of Regeneron Pharmaceuticals Inc. stock nowBull Run & High Conviction Trade Alerts - moha.gov.vn
Amgen Fights Regeneron’s Bid to Pause Eylea Antitrust Claims - Bloomberg Law News
Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis: A Strong Buy with 15.19% Return on Equity and 3.53% Potential Upside - DirectorsTalk Interviews
Regeneron announcements validate Apogee thesis, says Stifel By Investing.com - Investing.com UK
Assessing Regeneron Pharmaceuticals (REGN) Valuation After Recent Analyst Buy Upgrades - simplywall.st
Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Cuts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Cutaneous Squamous Cell Carcinoma Market Poised for Rapid - openPR.com
A big Wall Street flip just changed the Regeneron narrative - thestreet.com
Regeneron and Sanofi's Dupixent succeeds in late-stage study - MSN
Oregon Public Employees Retirement Fund Has $6.56 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Cerity Partners LLC - MarketBeat
What is the fair value of Regeneron Pharmaceuticals Inc. stock nowJuly 2025 Rallies & Verified Entry Point Signals - ulpravda.ru
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by SG Americas Securities LLC - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Raised to Strong-Buy at Zacks Research - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Upgraded by Wall Street Zen - MarketBeat
J&J Deal Adds To Trump Administration MFN Pricing Initiative - Citeline News & Insights
J&J Joins Trump Administration’s MFN Pricing Initiative - Citeline News & Insights
Regeneron (REGN) Upgraded to Strong Buy: What Does It Mean for the Stock? - sharewise.com
Bernstein Adjusts Price Target on Regeneron Pharmaceuticals to $911 From $818, Maintains Outperform Rating - marketscreener.com
Is Regeneron (REGN) Offering Value After Recent Share Price Strength And DCF Assessment - simplywall.st
Responsive Playbooks and the REGN Inflection - Stock Traders Daily
Regional Court Munich grants PI to Regeneron against generics in Eylea case - JUVE Patent
Regeneron Pharmaceuticals, Inc. $REGN Stake Lifted by Clear Harbor Asset Management LLC - MarketBeat
Will Regeneron Pharmaceuticals Inc. stock benefit from upcoming earnings reportsTrade Ideas & Reliable Entry Point Trade Alerts - ulpravda.ru
How interest rate cuts could boost Regeneron Pharmaceuticals Inc. stock2025 Volatility Report & Capital Efficiency Focused Ideas - ulpravda.ru
Regeneron Pharmaceuticals (NASDAQ:REGN) Director Sells $1,200,000.00 in Stock - MarketBeat
Will Regeneron Pharmaceuticals Inc. stock split again soon2025 Risk Factors & Daily Market Momentum Tracking - ulpravda.ru
Regeneron Pharmaceuticals Director Sells 1,500 Shares - TradingView — Track All Markets
Stock Market Recap: Will Regeneron Pharmaceuticals Inc. stock split again soonMarket Movement Recap & Weekly High Return Stock Forecasts - ulpravda.ru
Truist Securities Raises Price Target for REGN to $820, Maintains Buy Rating | REGN Stock News - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $820.00 Price Target at Truist Financial - MarketBeat
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity - Benzinga
Noesis Capital Mangement Corp Has $11.90 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
KLP Kapitalforvaltning AS Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Positive mid-stage results for Regeneron’s fasinumab - The Pharma Letter
MassMutual Private Wealth & Trust FSB Buys 1,267 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Diabetic Retinopathy Market to Witness Remarkable Growth With - openPR.com
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory - MSN
Analyst Upgrades And Short-Interest Drop Might Change The Case For Investing In Regeneron (REGN) - Yahoo Finance
Regeneron Just Moved From Underperform To BuyHere's Why - Benzinga
This Lowe's Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday (CORRECTED) - Benzinga
Regeneron Stock Lagged Behind the S&P 500 Last Year. Why This Firm Moved Off the Sidelines. - Barron's
Regeneron upgraded at BoA on Eylea HD, Dupixent, and pipeline - Seeking Alpha
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Regeneron Pharmaceuticals Inc Azioni (REGN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Bassler Bonnie L | Director |
Jan 07 '26 |
Sale |
800.00 |
1,500 |
1,200,000 |
1,703 |
0.55%
0.49%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):